{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:29:33Z","timestamp":1792067373870,"version":"4.4.0"},"reference-count":55,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Despite the advances in precision oncology through biomarker testing, not all patients are able to benefit from treatment decisions guided by tissue\u2010based testing like comprehensive genomic profiling (CGP). However, the application and integration of liquid biopsy testing into clinical practice has not been fully defined in Japan. Clinical records were retrieved from the data repository of the Center for Cancer Genomics and Advanced Therapeutics (C\u2010CAT) in Japan. All records related to FoundationOne Liquid tests were evaluated from the database's inception in June 2019 to June 2023. Outcomes of interest included treatment patterns before and after testing, as well as mutations of interest. The seven most frequent tumor types (pancreas, prostate, biliary tract, bowel, lung, stomach and ovary) were stratified as part of subgroup analyses. Of 7461 patient records, the most prevalent cancers were pancreatic (24.5%), prostate (15.8%), and biliary tract (11.2%) cancers. Following molecular tumor board (MTB) review, 5.8% of cases received new treatments, predominantly targeted therapy (41.7%) and chemotherapy (40.9%), with 2.1% participating in clinical trials. Median durations from specimen collection to post\u2010MTB treatment were 63\u2009days. Tests for patients with bowel cancer (70\/796; 8.8%) and lung cancer (57\/695; 8.2%) received genotype\u2010matched treatment most frequently, followed by tests for patients with prostate cancer (92\/1182; 7.8%). Access to CGP in Japan appears more limited compared to other high\u2010income countries. While CGP may be valuable for certain cancers, such as bowel, biliary, and prostate cancer, its benefit for other cancer types remains unclear.<\/jats:p>","DOI":"10.1111\/cas.70174","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:21:36Z","timestamp":1756275696000},"page":"3113-3124","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nationwide Real\u2010World Usage of Blood\u2010Based (Liquid) Biomarker Testing in Japan"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1788-559X","authenticated-orcid":false,"given":"Yasushi","family":"Yatabe","sequence":"first","affiliation":[{"name":"Department of Diagnostic Pathology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kotera","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5749-0993","authenticated-orcid":false,"given":"Shotaro","family":"Yasuoka","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine Okayama University Hospital  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13278-7"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14754"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-062917-011840"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535370217744775"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.03.007"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01351-y"},{"key":"e_1_2_12_8_1","unstructured":"Ministry of Health L and W \u201cMedical Fee Point List \u201d(2025) https:\/\/www.mhlw.go.jp\/content\/12404000\/001209396.pdf."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01844-1"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00291"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0417"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes12030349"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.013"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac034"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70071"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0902"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00736-1"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104108"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3862\/jcoloproctology.75.461"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12111870"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2016.09.008"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-025-02253-9"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3837"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081152"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060852"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14870-3"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09990-2"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.001"},{"key":"e_1_2_12_30_1","unstructured":"\u201cLynparza Approved in Japan for the Treatment of Advanced Ovarian Prostate and Pancreatic Cancers \u201d(2025) https:\/\/www.astrazeneca.com\/media\u2010centre\/press\u2010releases\/2020\/lynparza\u2010approved\u2010in\u2010japan\u2010for\u2010three\u2010cancers.html."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15518"},{"key":"e_1_2_12_32_1","unstructured":"\u201cLynparza Approved in Japan for 1st\u2010Line Maintenance Therapy in BRCA\u2010Mutated Advanced Ovarian Cancer \u201d(2025) https:\/\/www.astrazeneca.com\/media\u2010centre\/press\u2010releases\/2019\/lynparza\u2010approved\u2010in\u2010japan\u2010for\u20101st\u2010line\u2010maintenance\u2010therapy\u2010in\u2010brca\u2010mutated\u2010advanced\u2010ovarian\u2010cancer\u201019062019.html."},{"key":"e_1_2_12_33_1","unstructured":"The Japanese Urological Association \u201cClinical Practice Guideline for Prostate Cancer \u201d(2023) https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/23_prostatic_cancer_2023.pdf."},{"key":"e_1_2_12_34_1","volume-title":"Opinion Paper: Implications for Conducting Companion Diagnosis of PARP Inhibitors in Prostate Cancer","author":"The Japanese Urological Association","year":"2024"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4986365"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.256"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-00584-2"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535\u2010024\u201002173\u20100"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.52"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00243-0"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130206"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6317-6"},{"key":"e_1_2_12_44_1","unstructured":"Japan Pancreas Society \u201cClinical Practice Guidelines for Pancreatic Cancer \u201d(2022) https:\/\/suizou.org\/pdf\/pancreatic_cancer_cpg\u20102022.pdf."},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200123090153"},{"issue":"2","key":"e_1_2_12_46_1","first-page":"114","article-title":"Current Status and Prospects of Treatment Based on Molecular Diagnosis of Lung Cancer","volume":"41","author":"Tateishi K.","year":"2024","journal-title":"Official Journal of the Japan Association of Endocrine Surgeons"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep15020025"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5349"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.11.007"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2020.04.20"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00075"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac007"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133395"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071728"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.43392"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19110"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:40:44Z","timestamp":1762425644000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.70174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/cas.70174"],"URL":"https:\/\/doi.org\/10.1111\/cas.70174","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"2025-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}